Table 2 Clinicopathological data of breast cancer patients of validation cohort #2
From: Overexpression of circulating MiR-30b-5p identifies advanced breast cancer
Clinicopathological features | Localized BrC | Advanced BrC |
|---|---|---|
Patients (n) | 20 | 25 |
Age median (range) | 61 (39–71) | 53 (35–82) |
Molecular subtypea (%) | ||
Luminal A-Like | 7 (35.0) | 2 (8.0) |
Luminal B-Like | 13 (65.0) | 16 (64.0) |
HER2-enriched | – | 5 (20.0) |
Basal-like | – | 2 (8.0) |
Histological type (%) | ||
Invasive carcinoma of NST | 17 (85.0) | 18 (72.0) |
Invasive lobular carcinoma | 2 (10.0) | 4 (16.0) |
Other special subtype carcinoma | – | 2 (8.0) |
Mixed type carcinoma | 1 (5.0) | 1 (4.0) |
Grade (%) | ||
G1 | 4 (20.0) | – |
G2 | 9 (45.0) | 19 (76.0) |
G3 | 7 (35.0) | 6 (24.0) |
ER receptor status (%) | ||
Positive | 20 (100.0) | 18 (72.0) |
Negative | – | 7 (28.0) |
PR receptor status (%) | ||
Positive | 20 (100.0) | 14 (56.0) |
Negative | – | 11 (44.0) |
HER2 receptor status (%) | ||
Positive | 4 (20.0) | 11 (44.0) |
Negative | 16 (80.0) | 14 (56.0) |
T Stage (%) | ||
T1 | 20 (100.0) | 3 (12.0) |
T2 | – | 11 (44.0) |
T3 | – | 5 (20.0) |
T4 | – | 6 (24.0) |
N Stage (%) | ||
N0 | 20 (100.0) | – |
N1 | – | 4 (16.0) |
N2 | – | – |
N3 | – | 20 (80.0) |
Nx | – | 1 (4.0) |
Stage (%) | ||
IA | 20 (100.0) | n.a. |
IIIC | n.a. | 13 (52.0) |
IV | n.a. | 12 (48.0) |